Tremfya Market to Undertake Strapping Growth By 2033

 Tremfya Market Summary

The global tremfya market size was estimated at USD 3.67 billion in 2024 and is projected to reach USD 7.29 billion by 2033, growing at a CAGR of 7.60% from 2025 to 2033. The increasing prevalence of chronic plaque psoriasis and psoriatic arthritis drives greater demand for advanced biologic therapies.

Key Market Trends & Insights

• North America Tremfya market held the largest share of 85.46% of the global market in 2024.
• The Tremfya market in the U.S. is expected to grow significantly over the forecast period.
• By application, the plaque psoriasis segment held the highest market share of 87.0% in 2024.
• By distribution channel, the hospital pharmacies segment held the highest market share of 51.15% in 2024.

Market Size & Forecast

• 2024 Market Size: USD 3.67 Billion
• 2033 Projected Market Size: USD 7.29 Billion
• CAGR (2025-2033): 7.60%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

These autoimmune conditions continue to rise globally, resulting in a growing need for effective and long-term treatment options. Tremfya, a monoclonal antibody that targets interleukin-23 (IL-23), has delivered strong efficacy and durable outcomes in moderate-to-severe cases. Its consistent clinical performance and favorable safety profile have strengthened its acceptance among dermatologists and rheumatologists.

Access Full Report@ https://www.grandviewresearch.com/industry-analysis/tremfya-market-report

Janssen Pharmaceuticals ' strong marketing strategies and competitive positioning drive Tremfya’s commercial success. The drug has differentiated itself through superior efficacy data compared to some existing biologics, including TNF and IL-17 inhibitors. Head-to-head studies have shown Tremfya’s ability to achieve rapid skin clearance and sustained response, giving it a strategic advantage in the treatment landscape. For instance, In October 2024, Johnson & Johnson’s SPECTREM study showed Tremfya effectively cleared difficult psoriasis areas like the scalp, face, hands, feet, and genitals, with clearance rates up to 80%. Most patients maintained clear or almost clear skin through week 48. The treatment also significantly improved patients’ quality of life by reducing symptoms like itch and pain.

Ongoing clinical research and lifecycle management initiatives support the Tremfya market's future growth. New clinical trials are exploring expanded applications, such as hidradenitis suppurativa and Crohn’s disease, which could significantly widen its therapeutic scope. The drug’s manufacturer also invests in real-world evidence studies to validate its effectiveness in diverse populations. The growing interest in precision medicine and biomarker-driven therapies is increasing the relevance of IL-23 inhibitors in personalized treatment regimens. Partnerships with specialty pharmacies and streamlined distribution networks enhance availability in high-demand markets. The company’s continued focus on physician education and patient support programs reinforces brand loyalty.

Key Tremfya Company Insights

Johnson & Johnson Services, Inc. remains the key player in the Tremfya market, leveraging its strong global presence, robust regulatory approvals, and comprehensive distribution networks. Strategic pricing, innovative research, and effective supply chain operations influence competitive dynamics in this market. Emerging players such as Arven Pharmaceuticals from Turkey, Biocon from India, and MorphoSys from Germany are gradually expanding their presence by focusing on clinical development and cost-effective production. These companies aim to challenge established players by introducing new formulations and targeting underserved markets. As healthcare providers increasingly seek affordable and effective treatment options, competition in the Tremfya market is expected to intensify. Overall, the market is projected to grow significantly throughout the forecast period.

Key Tremfya Companies:

The following are the leading companies in the tremfya market. These companies collectively hold the largest market share and dictate industry trends.

• Johnson & Johnson Services, Inc.

Recent Developments

• In March 2025, Johnson & Johnson reported that Icotrokinra significantly improved plaque psoriasis severity with rapid and sustained PASI score reductions. The treatment showed a strong safety profile and was well tolerated by patients. These results suggest Icotrokinra could become a new standard therapy for moderate-to-severe plaque psoriasis.
• In March 2025, Johnson & Johnson announced the FDA approval of Tremfya as the first IL-23 inhibitor with subcutaneous and intravenous options for adults with moderate to severely active Crohn’s disease. This approval offers flexible treatment methods to improve patient outcomes. It also expands Tremfya’s use beyond psoriasis and arthritis to include Crohn’s disease.
• In May 2024, Johnson & Johnson announced that Tremfya’s phase 3 study showed superior results versus ustekinumab in treating Crohn’s disease. The data highlighted Tremfya’s strong efficacy for moderate to severe cases. This advancement reinforced Tremfya’s potential as a key therapy in inflammatory bowel disease.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.